Compare LKQ & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LKQ | PRAX |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 8.8B |
| IPO Year | 2003 | 2020 |
| Metric | LKQ | PRAX |
|---|---|---|
| Price | $33.12 | $310.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $44.33 | ★ $397.85 |
| AVG Volume (30 Days) | ★ 3.0M | 645.0K |
| Earning Date | 02-19-2026 | 02-27-2026 |
| Dividend Yield | ★ 3.60% | N/A |
| EPS Growth | ★ 0.63 | N/A |
| EPS | ★ 2.69 | N/A |
| Revenue | ★ $14,097,000,000.00 | $7,463,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.75 | $15,003.90 |
| P/E Ratio | $12.36 | ★ N/A |
| Revenue Growth | N/A | ★ 364.98 |
| 52 Week Low | $28.13 | $26.70 |
| 52 Week High | $44.82 | $326.91 |
| Indicator | LKQ | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 58.58 |
| Support Level | $32.57 | $289.50 |
| Resistance Level | $37.13 | $326.83 |
| Average True Range (ATR) | 0.96 | 19.66 |
| MACD | -0.04 | -1.65 |
| Stochastic Oscillator | 33.93 | 73.25 |
Since forming in 1998 to consolidate the auto salvage business in the United States, LKQ has developed into a leading distributor of aftermarket and recycled auto parts with around 1,500 facilities across North America and Europe. The company primarily sells into the professional channel and offers an assortment of collision and mechanical parts to both body shops and mechanical repair shops. It also continues to operate more than 70 LKQ pick-your-part junkyards. Separate from the self-service business, LKQ usually purchases around 250,000 salvage vehicles annually that are used to extract vehicle parts for resale.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.